[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356308-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356308-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","phosphoglucomutase-5-suppresses-gallbladder-cancer-progression-by-inhibiting-lactate-driven-stat3-signaling","Phosphoglucomutase 5 suppresses gallbladder cancer progression by inhibiting lactate-driven STAT3 signaling","","Gallbladder cancer (GBC) is an aggressive biliary malignancy with limited treatment options. Phosphoglucomutase 5 (PGM5), a glucose-metabolism enzyme, is significantly downregulated in GBC tissues, and low PGM5 expression associates with poor prognosis. Integrated bioinformatics links PGM5 loss to enhanced glycolysis and activation of STAT3 signaling. Mechanistically, PGM5 reduces lactate production by downregulating LDHA, lowering STAT3 phosphorylation. Exogenous lactate or 2-DG alters these phenotypes; in vivo, PGM5 restrains xenograft growth and decreases LDHA, p-STAT3, and intratumoral lactate.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/phosphoglucomutase-5-suppresses-gallbladder-cancer-progression-by-inhibiting-lactate-driven-stat3-signaling/356308/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/phosphoglucomutase-5-suppresses-gallbladder-cancer-progression-by-inhibiting-lactate-driven-stat3-signaling/356308.png","ImageObject",300,407,{"name":42,"@type":43},"Emma Wilson","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main role of PGM5 in gallbladder cancer progression?","Question",{"text":63,"@type":64},"PGM5 acts as a tumor suppressor in GBC by inhibiting pathways that promote tumor growth, migration, and invasion while promoting apoptosis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does PGM5 affect the lactate-STAT3 signaling axis?",{"text":68,"@type":64},"PGM5 suppresses lactate production by downregulating LDHA, which decreases phosphorylation of STAT3.",{"name":70,"@type":61,"acceptedAnswer":71},"What experimental evidence supports the lactate dependence of PGM5’s anti-tumor effects?",{"text":72,"@type":64},"The anti-tumor effects of PGM5 are reversed by exogenous lactate supplementation, and the glycolytic inhibitor 2-DG abrogates oncogenic phenotypes induced by PGM5 knockdown.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356308,1790169840,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Translational Oncology 65 (2026) 102678  \nContents lists available at ScienceDirect Translational Oncology  \njournal [homepage:](homepage: www.elsevier.com/locate/tranon)[ www.elsevier.com/locate/tranon](homepage: www.elsevier.com/locate/tranon)  \n| Phosphoglucomutase 5 suppresses gallbladder cancer progression by inhibiting lactate-driven STAT3 signaling\u003Cbr>Wencong Ma 1, Cheng Zhang 1, Anjiang Gou 1, Mingtai Hu , Yao Huang , Xiaoqing Jiang *, Jianyang Ao *, Jinghan Wang *\u003Cbr>Department of Hepatobiliary Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, China |  |  |\n| --- | --- | --- |\n| A R T I C L E I N F O |  | A B S T R A C T |\n| Keywords: Gallbladder cancer PGM5\u003Cbr>Glycolysis Lactate |  | Gallbladder cancer (GBC) is a highly aggressive malignancy of the biliary tract with limited therapeutic options. Phosphoglucomutase 5 (PGM5), a key enzyme in glucose metabolism, has been implicated as a tumor suppressor in several cancers, yet its role and mechanism in GBC remain unclear. Here, we demonstrate that PGM5 is significantly downregulated in GBC tissues, and its low expression correlates with poor prognosis. Using integrated bioinformatic analysis, we found that PGM5 loss is associated with enhanced glycolysis and activation of the STAT3 signaling pathway. Functionally, PGM5 overexpression significantly inhibited GBC cell proliferation, migration, and invasion, and promoted apoptosis, whereas PGM5 knockdown exerted the opposite effects. Mechanistically, PGM5 suppressed lactate production by downregulating lactate dehydrogenase A (LDHA), leading to decreased phosphorylation of STAT3. The anti-tumor effects of PGM5 were reversed by exogenous lactate supplementation, and the glycolytic inhibitor 2-DG abrogated the oncogenic phenotypes induced by PGM5 silencing. In a mouse xenograft model, PGM5 overexpression significantly restrained tumor growth, reduced LDHA and p-STAT3 levels, and decreased intratumoral lactate content. Our findings reveal that PGM5 acts as a tumor suppressor in GBC through disruption of the lactate-STAT3 signaling axis, highlighting its potential as a therapeutic target for metabolic intervention in GBC. |\n\nIntroduction  \nGallbladder cancer (GBC) represents the leading type of biliary tumor, ranking first in incidence among tumors of the biliary tract and sixth among digestive system malignancies [1]. This disease displays highly aggressive biological behavior, with early local invasion including liver metastasis, which often leads to late-stage diagnosis and poor overall prognosis [2–4]. Studies show that the 5-year survival rate can reach 60 % in patients eligible for early surgical treatment, whereas it sharply drops to 4 %–10 % in advanced-stage patients [5,6]. Currently, radical surgical resection remains the only potentially curative treatment, yet only 10 %–30 % of patients meet the criteria for surgery at the time of diagnosis [5–7]. Therefore, a comprehensive understanding of the pathways driving GBC development, along with pinpointing critical molecules that govern its progression, has become  \nan urgent requirement for enhancing patient outcomes and creating novel therapeutic strategies.  \nCellular metabolic reprogramming is characteristic of malignant tumors, with the “Warburg effect”-whereby tumor cells utilize glycolysis over oxidative phosphorylation despite oxygen availability, causing lactate buildup-contributing significantly to tumor progression, invasion, and modulation of antitumor immunity [8–10]. Lactate accumulation via the Warburg effect acidifies the tumor microenvironment (pH 6.0–6.5), directly impairing the function of effector immune cells such as CD8+ T cells and NK cells, while promoting the polarization of M2-type tumor-associated macrophages (TAMs) and activation of regulatory T cells (Tregs) [11–14]. The STAT signaling pathway is central to this process; for example, in the pancreatic cancer microenvironment, IL-6 secreted by TAMs promo","cbCaighAx7rIYLvo","https://ap.wps.com/l/cbCaighAx7rIYLvo","pdf",6778901,"English","# Introduction\n## Gallbladder cancer burden and prognosis\n## Metabolic reprogramming, lactate, and immune modulation\n## STAT3 signaling in tumor progression\n# Ethics statement\n# Article metadata (DOI, authors, correspondence)\n# Abstract / Key findings","[{\"question\":\"What is the main role of PGM5 in gallbladder cancer progression?\",\"answer\":\"PGM5 acts as a tumor suppressor in GBC by inhibiting pathways that promote tumor growth, migration, and invasion while promoting apoptosis.\"},{\"question\":\"How does PGM5 affect the lactate-STAT3 signaling axis?\",\"answer\":\"PGM5 suppresses lactate production by downregulating LDHA, which decreases phosphorylation of STAT3.\"},{\"question\":\"What experimental evidence supports the lactate dependence of PGM5’s anti-tumor effects?\",\"answer\":\"The anti-tumor effects of PGM5 are reversed by exogenous lactate supplementation, and the glycolytic inhibitor 2-DG abrogates oncogenic phenotypes induced by PGM5 knockdown.\"}]","Phosphoglucomutase 5 suppresses gallbladder cancer progression by inhibiting lactate-driven STAT3 signaling | PDF",1790124548,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/537f35af36b7165abde7d335ba08e65b.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5f70d0601206b1c10b8e28ff2189cf0e.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/774df684928d745678ad15940475deeb.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9c6d64a93b76013afca6404ae7955c57.webp",980,1306]